New Zealand markets closed

Clarivate Plc (CLVT)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
5.56+0.09 (+1.65%)
At close: 04:00PM EDT
5.60 +0.04 (+0.72%)
After hours: 05:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close5.47
Open5.48
Bid5.03 x 4000
Ask0.00 x 4000
Day's range5.45 - 5.60
52-week range5.19 - 10.03
Volume6,748,427
Avg. volume4,590,420
Market cap3.715B
Beta (5Y monthly)1.20
PE ratio (TTM)N/A
EPS (TTM)-1.65
Earnings date01 Aug 2024 - 05 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.94
  • PR Newswire

    Clarivate Launches IP Collaboration Hub

    Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today launched the IP Collaboration Hub™ at the 2024 Clarivate Ignite conference held in San Diego, U.S. The new solution integrates with Clarivate IP management systems (IPMS) to provide a central hub for collaborating with local agents worldwide.

  • PR Newswire

    Clarivate Reveals World's Leading and Trusted Journals with the 2024 Journal Citation Reports

    Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released the 2024 update to the Journal Citation Reports™ (JCR™). The reports provide an essential and comprehensive resource of high-quality journals, ranked by field to enable academic institutions, researchers and publishers to gauge the significance of journals in the global research landscape. Changes to journal rankings include the addition of the Emerging Sources Citation Index.

  • PR Newswire

    Clarivate Identifies Seven Innovators in Antibody Drug Conjugates in New Companies to Watch Report

    Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has released its annual Companies to Watch report, highlighting seven innovative companies revolutionizing drug discovery and development. These companies are advancing antibody-drug conjugates (ADCs) to deliver highly targeted cancer treatments with minimal side effects. Based on data, insights and analysis of drug benefits, financing and R&D activity, the report explores why these companies are significant inn